Answers are grounded in this paper and cite their sources.
In this pharmacogenetic study, riboflavin appears to be more effective in patients with migraine with non-H mitochondrial DNA haplotypes. The underlying mechanisms are unknown, but could be related to the association of haplogroup H with increased activity in complex I, which is a major target for riboflavin. Our results may have ethnic implications, since haplogroup H is chiefly found in the European population.
No takes yet. Share an insight, caveat, or question.
Lorenzo et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: